GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.
Sarcopenia and poor nutrition are often silent threats in chronic liver disease, yet they drastically impact outcomes. Joining Dr. Peter Buch to discuss strategies for recognizing and addressing malnutrition early to improve long-term liver health is Dr. Ashwani Singal. Dr. Singal is a Professor of Medicine at the University of Louisville School of Medicine.
As the advanced treatment landscape for inflammatory bowel disease continues to expand, selecting the right therapies has become more complex, with efficacy, safety, patient preferences, disease phenotypes, and more as factors to consider. Learn how to effectively navigate these therapeutic options for ulcerative colitis and Crohn’s disease with Dr. Peter Buch and Dr. David Fudman, Assistant Professor and Director of Inflammatory Bowel Disease Clinics at the University of Texas Southwestern Medical Center.
When are ostomies necessary in patients with inflammatory bowel disease? Join Dr. Peter Buch and Dr. Stefan Holubar, Director of Research at the IBD Surgery Section at the Cleveland Clinic, as they explore key surgical considerations for both ulcerative colitis and Crohn’s disease, including when to consider temporary versus permanent ileostomies, how to manage complications like anastomotic leaks, and what factors influence the decision to delay or avoid ileal pouch creation.
Colonic perforations during colonoscopy are rare, but when they occur, taking swift and informed action is critical, particularly to avoid surgical intervention. Joining Dr. Peter Buch to offer his insights on perforation prevention, risk-reduction techniques, and repair strategies is Dr. Mark Benson, an advanced endoscopist and Associate Professor in the Division of Gastroenterology and Hepatology at the University of Wisconsin School of Medicine.
Topical hemostatic agents play a key role in managing complex bleeding cases, but there’s a lot to keep in mind when selecting which agent to use, like their mechanism and efficacy. Joining Dr. Peter Buch to share top considerations and best practices for using topical hemostatic agents is Dr. J Andy Tau, a board-certified gastroenterologist at Austin Gastroenterology in Texas.
While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.
For many patients with Crohn’s disease, surgery is necessary due to complications like strictures and fistulas. Dr. Elisa Boden explores risk factors and potential complications, which she spoke about at the 2025 Crohn’s and Colitis Congress. Dr. Boden is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
While inflammatory bowel disease (IBD) does not typically cause significant problems in pregnancy, it’s still essential to discuss potential impacts with patients and monitor them closely. Dr. Sara Horst, a Professor of Medicine at Vanderbilt University Medical Center, joins GI Insights to discuss important considerations for pregnant patients with IBD.
For patients with Crohn’s disease who require surgery, a variety of risk factors are involved in postoperative recovery and disease control. Learn how prehabilitation programs and lifestyle modifications can reduce complications during and after surgery with Dr. Elisa Boden, an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at Oregon Health and Science University.
With the constant ups and downs of inflammatory bowel disease (IBD), consistent monitoring can help provide patient-centric care. Dr. Shalini Prasad and Dr. Sriram Muthukumar, co-founders of EnLiSense, join GI Insights to discuss the wearable device they developed to track inflammation markers in IBD patients. Dr. Prasad is the Head of the Department of Bioengineering at the University of Texas at Dallas, and Dr. Muthukumar is the CEO of EnLiSense.
Recent changes to the American College of Gastroenterology’s guidelines on H. pylori treatment provide recommendations for antibiotic susceptibility and optimal patient management. Dr. Peter Buch sits down with the lead author of these guidelines, Dr. William Chey, to learn more about implications for clinical practice. Dr. Chey is the Chief of the Division of Gastroenterology and Hepatology, the H. Marvin Pollard Professor of Gastroenterology, and a Professor of Nutrition Sciences at the University of Michigan.
The American Society for Gastrointestinal Endoscopy (ASGE) recently released a new guideline on when to use endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) in managing early esophageal and gastric cancers. To learn more about when to use each approach, Dr. Peter Buch sits down with guideline co-author Dr. Vivek Kaul. Dr. Kaul is also the Segal-Watson Professor of Medicine at the University of Rochester Medical Center in New York.
Patients with inflammatory bowel disease (IBD) can experience a variety of extraintestinal manifestations (EIMs), including joint and eye pain and skin rashes. Dr. Peter Buch sits down with Dr. David Hudesman to discuss the impacts of these EIMs and explore best practices for patient management. Dr. Hudesman is a Professor of Medicine at NYU Grossman School of Medicine and Co-Director of NYU Langone’s Inflammatory Bowel Disease Center.
With so many therapeutic options for Crohn’s disease and ulcerative colitis, it can be challenging to determine which one best matches your patient’s needs and preferences. Onset of action, risk of infections, disease location, and therapeutic goals are all key factors in the decision-making process. To learn more about these considerations, Dr. Peter Buch sits down with Dr. David Hudesman and explores the current therapeutic landscape for inflammatory bowel disease.
Recent research explored the development, validation, and implications of the GEM integrative risk score (GEM-IRS). To learn how this innovative model helps predict the future risk of Crohn’s Disease in healthy first-degree relatives, Dr. Charles Turck speaks with Dr. Sun-Ho Lee, Assistant Professor and clinician scientist at the Inflammatory Bowel Disease Centre at Mount Sinai Hospital in Toronto, Canada.
While neuromodulators are primarily used to treat psychiatric disorders, they can also help normalize symptoms of irritable bowel syndrome by targeting the gut-brain axis. In fact, about half of all patients with IBS have the potential to benefit from neuromodulators. Dr. Douglass Drossman joins Dr. Peter Buch to discuss his research on how various neuromodulators can provide relief for IBS patients. Dr. Drossman is the President of the Drossman Center of Education and Practice of Psychosocial Care and Drossman Consulting as well as a Professor Emeritus of Medicine and Psychiatry at the University of North Carolina School of Medicine.
While colorectal cancer is the second most common cause of cancer deaths, only a third of people between the ages of 45 and 75 are compliant with screening recommendations. However, cell-free DNA blood-based tests could become a new option for colorectal cancer screening. Dr. Peter Buch sits down with GI expert Dr. William Grady to discuss the efficacy of this new test and where it is in the FDA approval process.
Join Dr. Peter Buch as he speaks with Dr. Kyle Staller, Director of the Gastrointestinal Motility Laboratory at Mass General and Assistant Professor of Medicine at Harvard Medical School, about uncovering the cause of a patient’s bloating and determining how to manage it.
The complexities of gastroparesis can make the disease difficult to diagnose and treat. To help us overcome these challenges, Dr. Kyle Staller joins Dr. Peter Buch to share his preferred strategies for managing patients with gastroparesis. Not only is Dr. Staller an Assistant Professor of Medicine at Harvard University, but he’s also the Director of the GI Motility Lab at the Massachusetts General Hospital.
